- $404.00m
- $422.32m
- $5.00m
Brief: Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
Brief: Nippon Kayaku: Acquired 1.5% Stake In Adlai Nortye For $40 Million By Subscribing To Third-Party Allotment At Its IPO
U.S. STOCKS ON THE MOVE-Mercato, Baytex, Ball Corp
Cancer biotech Adlai plunges in U.S. debut after pricing IPO
Brief: Adlai Nortye Ltd Announces Pricing Of Initial Public Offering